Avista-backed Acino, a Swiss pharmaceutical company, completed the acquisition of the drug portfolio of Takeda Pharmaceutical in EMEA, a global, R&D-driven biopharmaceutical firm, for $200m. This is the third transaction in FY19 that furthers Takeda’s strategy to focus on business areas core to its long-term growth and facilitate rapid deleveraging following its acquisition of Shire. “The divestment of non-core assets sold in NEMEA represents the continued execution of our strategy to optimize our portfolio, invest in the defined core business areas, and accelerate our progress toward reaching our target leverage ratio,” Costa Saroukos, Takeda Chief Financial Officer.